Vimentin (VIM) Mouse Monoclonal Antibody [Clone ID: RV202]
CAT#: BM6008P
Vimentin (VIM) mouse monoclonal antibody, clone RV202, Purified
Need it in bulk or conjugated?
Get a free quote
CNY 6,380.00
货期*
5周
规格
Specifications
Product Data | |
Clone Name | RV202 |
Applications | FC, IF, IHC, WB |
Recommend Dilution | Immunoblotting. Flow Cytometry. Immunocytochemistry. Immunofluorescence. Immunohistochemistry on Frozen Sections. Immunohistochemistry on Paraffin Sections. Recommended Dilutions: 1/100-1/200 for Flow Cytometry, and for Immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1/100-1/1000 for Immunoblotting applications. |
Reactivity | Canine, Chicken, Goat, Hamster, Human, Monkey, Mouse, Porcine, Rat, Xenopus, Zebrafish |
Host | Mouse |
Clonality | Monoclonal |
Immunogen | Cytoskeletal Vimentin extract of calf lens. |
Specificity | RV202 reacts exclusively with Vimentin, which is expressed in mesenchymal cells and mesenchymal derived tumors e.g. lymphoma, sarcoma and melanoma. |
Formulation | PBS State: Purified State: Liquid purified IgG fraction Preservative: 0.09% Sodium Azide |
Concentration | lot specific |
Conjugation | Unconjugated |
Storage Condition | Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freeze-thaw cycles. |
Gene Name | vimentin |
Database Link | |
Background | Vimentin (57 kDa) is the intermediate filament protein (IFP) of mesenchymal cells. This IFP however often deviates from the tissue-specific and developmentally regulated pattern of expression. Besides its typical expression in most cultured cells, vimentin is also expressed together with several other IFPs during early stages of development. As differentiation proceeds, vimentin is exchanged for the tissue-specific intermediate filament type. Also in cancers, vimentin is often expressed in addition to the tissue-specific IFP. |
Synonyms | VIM |
Reference Data |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...